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background: To compare the effects of two of the most effective lipid--lowering therapies with similar LDL--cholesterol reduction capacity on the 
innate and adaptive immune responses through the  evaluation of autoantibodies anti-- oxidized LDL (anti--oxLDL Abs) and electronegative LDL 
[LDL(--)] levels.
methods: We performed a prospective, randomized, open label study,with parallel arms  and blinded endpoints. One hundred and twelve subjects 
completed the study protocol and received rosuvastatin 40 mg or ezetimibe/simvastatin 10/40 mg for 12 weeks. Lipids, apolipoproteins, LDL(--), 
and anti--oxLDL Abs (IgG) were assayed at baseline and end of study.
results: Main clinical and laboratory characteristics were comparable at baseline. Lipid modifications were similar in both  treatment arms, 
however, a significant raise in anti- --oxLDL Abs levels was observed in subjects treated  with rosuvastatin (p=0.026 vs. baseline), but not in those 
receiving simvastatin/ezetimibe. (p=0.233  vs. baseline), thus suggesting modulation of adaptive immunity by a potent statin. Titers of LDL(--) were 
not modified by the treatments. 
conclusions: Considering atherosclerosis as an immune disease, this study adds new information, showing that under similar LDL--cholesterol 
reduction, the choice of lipid--lowering therapy can differently modulate immune responses.
